The Reduction of both Cyclophilin B and HCV-RNA by the Cyclophilin Inhibitor Debio-025 Confirms the Importance of Cyclophilin B for HCV replication in Man | Debio 025 | /

Home|Careers|Contact us

News

20.11.2008
Debiopharm and Aurigene sign licensing agreement for the development and commercialisation of Debio 0617, a novel inhibitor of an undisclosed oncology pathway
17.11.2008
Debiopharm and Pharmaleads sign license agreement for Debio 0827 or PL37 in treatment of chronic pain conditions

The Reduction of both Cyclophilin B and HCV-RNA by the Cyclophilin Inhibitor Debio-025 Confirms the Importance of Cyclophilin B for HCV replication in Man

P. Ballay, R. Flisiak, A. Horban, C. aeschlimann, J.M. Dumont, H. Porchet, P. Scalfaro, R. Crabbé

42nd Anual Meeting of the European Association for the Study of the Liver - Barcelona/Spain

Abstract + Poster